Scarica l'app Stockscreener
5.36
3.42%
-0.19
Dopo l'orario di chiusura:
5.42
0.06
+1.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACHV Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.55
Aprire:
$5.59
Volume 24 ore:
1.66M
Relative Volume:
1.20
Capitalizzazione di mercato:
$550.25M
Reddito:
-
Utile/perdita netta:
$-54.65M
Rapporto P/E:
-4.1396
EPS:
-1.2948
Flusso di cassa netto:
$-49.47M
1 W Prestazione:
-6.78%
1M Prestazione:
+1.32%
6M Prestazione:
+26.71%
1 anno Prestazione:
+79.87%
Intervallo 1D:
$5.32
$5.63
Intervallo di 1 settimana:
$5.315
$6.16
Portata 52W:
$2.00
$6.16
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Nome
Achieve Life Sciences Inc
Settore
Industria
Telefono
425-686-1500
Indirizzo
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
5.36 | 574.89M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2025-11-25 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-08-21 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2024-09-27 | Iniziato | Raymond James | Strong Buy |
| 2023-05-10 | Reiterato | Maxim Group | Buy |
| 2021-06-23 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Achieve Life Sciences Inc Borsa (ACHV) Ultime notizie
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
Lakeside Advisors, INC.'s Achieve Life Sciences Inc(ACHV) Holding History - GuruFocus
[ARS] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Achieve Life Sciences (NASDAQ: ACHV) plans vote to double share authorization - Stock Titan
ACHV News | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
ACHV Stock Chart | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences (ACHV) director awarded 47,250 options at $5.24 strike - Stock Titan
Achieve Life (ACHV) director receives 47,250 options at $5.24 strike - Stock Titan
ACHIEVE Life Sciences (ACHV) director reports no beneficial ownership on Form 3 - Stock Titan
Achieve Life Sciences (ACHV) director Farrow files Form 3 with no share ownership - Stock Titan
Achieve Life Sciences, Inc. Announces Board Appointments - marketscreener.com
Achieve Life Sciences appoints two new directors to board and committees - Investing.com Nigeria
Achieve Life Sciences, Inc. Files Form 8-K Current Report with SEC on May 29, 2026 - Minichart
Achieve Life Sciences appoints two new directors to board and committees By Investing.com - Investing.com South Africa
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors - The Globe and Mail
[8-K] ACHIEVE LIFE SCIENCES, INC. Reports Material Event - Stock Titan
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences (ACHV) asks shareholders to double authorized common shares to 300M - Stock Titan
Achieve Life Sciences 4Q Loss/Shr 28c >ACHV - Moomoo
Achieve Life Sciences Completes Tech Transfer to Adare Pharma Solutions - Contract Pharma
[EFFECT] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Achieve Life Sciences Q1 2026 Earnings: Narrower-than-Expected Loss Drives OptimismEnergy Earnings Report - thelegaladvocate.com
Canaccord reiterates Achieve Life Sciences stock rating on safety data By Investing.com - Investing.com South Africa
Achieve Life Sciences (ACHV) price target decreased by 14.04% to 12.82 - MSN
Canaccord reiterates Achieve Life Sciences stock rating on safety data - Investing.com
Q3 2025 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
Achieve Life Sciences presents long-term cytisinicline data By Investing.com - Investing.com Australia
Achieve Life Sciences presents long-term cytisinicline data - Investing.com UK
Achieve Life Sciences, Inc.: cytisinicline data indicate well-tolerated safety over 52 weeks for adults quitting smoking - Traders Union
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment - The Manila Times
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline in Smoking Cessation at ATS 2026 - Quiver Quantitative
Achieve Life Sciences Q1 earnings call highlights - MSN
Achieve (ACHV) Q1 2026 Earnings Transcript - AOL.com
Q2 Earnings Forecast for ACHV Issued By Zacks Research - MarketBeat
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectations - Investing.com Nigeria
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
HC Wainwright Has Optimistic Outlook of ACHV Q2 Earnings - MarketBeat
[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Director at ACHIEVE Life Sciences (ACHV) granted 47,250 stock options at $5.59 - Stock Titan
Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission - Seeking Alpha
Achieve Life Sciences, Inc.Common Shares (NQ: ACHV - FinancialContent
Achieve Life Sciences Inc Azioni (ACHV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Achieve Life Sciences Inc Azioni (ACHV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):